News

Filter

1 to 9 of 56 results

AbbVie fourth-qtr beats forecasts, but posts Shire-associated $810 million loss

AbbVie fourth-qtr beats forecasts, but posts Shire-associated $810 million loss

31-01-2015

US drugmaker AbbVie on Friday announced financial results for the fourth quarter and full year 2014,…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsFinancialHumiraPharmaceuticalViekira Pak

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

New drugs and biosimilars to drive rheumatoid arthritis to $19.3 billion by 2023

13-01-2015

The launch of novel drugs and biosimilars will drive steady growth in the global rheumatoid arthritis…

AmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingPharmaceuticalResearchUSA

Zydus launches world’s first biosimilar of Humira

Zydus launches world’s first biosimilar of Humira

09-12-2014

A biosimilar of AbbVie’s blockbuster drug Humira (adalimumab) has been launched in India by generic…

AbbVieAnti-Arthritics/RheumaticsBiosimilarsHumiraIndiaMarkets & MarketingZydus Cadila

Stada Arz and mAbxience to negotiate over adalimumab biosimilar

21-11-2014

German drugmaker Stada Arzneimittel and the biotech specialist mAbxience have agreed to negotiate over…

AbbVieadalimumabAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyHumiraLicensingMabxienceSTADA Arzneimittel

EMA responds to Ombudsman questioning of AbbVie trial redactions

13-11-2014

The European Medicines Agency says it has taken note of the European Ombudsman’s recent remarks on…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulationResearch

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

AbbVie, still fuelled by Humira, beats own and analysts’ forecasts

01-11-2014

Just a couple of weeks after abandoning its $54 billion “tax inversion” motivated takeover of Ireland-headquartered…

AbbVieAnti-Arthritics/RheumaticsFinancialHumiraPharmaceuticalShireUSA

New Ph III data to support filing for AbbVie’s Humira in HS

13-10-2014

US pharma company AbbVie has reported new data with its mega blockbuster arthritis drug Humira (adalimumab)…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

Ph III study of Amgen’s Humira biosimilar ABP 501 meets endpoint in psoriasis

09-10-2014

US biotech major Amgen says its Phase III study evaluating the efficacy and safety of its biosimilar…

AbbVieABP 501AmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyDermatologicalsHumiraResearchUSA

1 to 9 of 56 results

COMPANY SPOTLIGHT

Menarini

Back to top